US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform

GENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment of cancers.

View PDF